Some people have reported their experiences with semaglutide and discussed whether it might be related to yeast infections theyve experienced while taking the medication
[73] [74] Over two years of follow-up, tirzepatide decreased participants' risk of major cardiovascular (CV) complicationsa combined endpoint including urgent heart failure visits, hospitalizations, more frequent diuretic treatment, and CV mortalityby 38% compared to a placebo
How does the body get to the point, where someone becomes weight loss resistant
Every drug we have discussed so far targets one pathway
Look for signs of metabolic dysfunction, abnormal liver enzymes, and fatty liver on imaging, even in patients who appear lean
It drives insulin resistance, raises cardiovascular risk, and fuels the cluster of conditions known as metabolic syndrome